Incorporating SGLT2i and GLP-1RA for Cardiovascular and Kidney Disease Risk Reduction: Call for Action to the Cardiology Community

Authors calls for coordinated and multifaceted interventions to increase adoption of SGLT-2i and GLP-1RA as part of routine cardiovascular and kidney care by reframing them as primarily cardiovascular and kidney disease risk-reducing agents with a side effect of glucose-lowering.

Circulation